Zymeworks Inc(ZYME-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low25.40
Day High26.32
Open:25.78
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
Condo and office towers line the downtown skyline with the north shore mountains in the distance, in Vancouver, on Friday, July 4, 2025. THE CANADIAN PRESS/Darryl Dyck
the globe and mail

Zymeworks offers US$929-million for COPD drug maker Theravance

OMERS life sciences arm is providing US$350-million in additional financing for the deal
Tipranks
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)
Tipranks
Jefferies Sticks to Their Buy Rating for Zymeworks (ZYME)
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)
Tipranks
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Celldex (CLDX) and ACADIA Pharmaceuticals (ACAD)
Tipranks
Zymeworks to Acquire Theravance in Strategic Merger
GlobeNewswire
Zymeworks to Acquire Theravance Biopharma, Inc.
Tipranks
H.C. Wainwright Sticks to Their Buy Rating for Zymeworks (ZYME)
Tipranks
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)
Tipranks
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)
Newswire.ca
Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery
GlobeNewswire
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Tipranks
Analysts Offer Insights on Healthcare Companies: Perrigo Company (PRGO) and Zymeworks (ZYME)
Tipranks
Zymeworks and BeOne: Long‑Term Cancer Study Update Supports Durable Drug Story
Tipranks
Zymeworks (ZYME) Gets a Buy from Wells Fargo
Tipranks
Zymeworks Earnings Call Balances Promise and Risk
Tipranks
Zymeworks Authorizes 2026 Share Repurchase Program, Affirms Liquidity
GlobeNewswire
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
Tipranks
Citi Reaffirms Their Buy Rating on Zymeworks (ZYME)

Profile

Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.